4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit

Lipid-based nanoparticles are evolving-faster, safer and more precise than ever. With traditional LNPs struggling to reach tissues beyond the liver, the industry is doubling down on next generation technologies for extra-hepatic. In 2024 alone, Novo Nordisk invested $600M in NanoVation to push genetic medicines further, while Nanite and Saliogen joined forces to pioneer non-viral, lung-targeting nanoparticles.

Time: 8:00 AM - 4:30 PM